Multiple Sclerosis Centers of Excellence
Natalizumab (Tysabri®) is a medication administered by IV infusion, over one hour every four weeks, for the treatment of relapsing forms of MS. Natalizumab is theorized to block molecular interaction of alpha-4-beta-integrin expressed by inflammatory cells with VCAM-1 on vascular endothelial cells. The humanized monoclonal antibody binds to alpha 4/beta 1 integrin on activated lymphocytes and monocytes, and blocks leukocyte passage across the blood brain barrier.
The medication must be prescribed through the Tysabri® Outreach: Unified Commitment to Health (TOUCH®) program.
For Additional Information
- VA Natalizumab (Tysabri®) Criteria for Use
- VA Natalizumab (Tysabri®) Drug Monograph
- VA Adverse Drug Events Reporting System
- Natalizumab (Tysabri®) Prescribing Information for Healthcare Professionals
- Natalizumab (Tysabri®) Medication Guide for Patients
- Tysabri® (website for patients and healthcare professionals)